A novel algorithm to redefine blood-based tumor mutational burden for optimized prediction of clinical benefits from immunotherapy.

被引：1
|
作者：
Wang, Zhijie
Wang, Guoqiang
Duan, Jianchun
Zhao, Jing
Zhao, Zhengyi
Bai, Hua
Wang, Shuhang
Cai, Shangli
Wang, Jie
机构：
[1] Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, State Key Lab Mol Oncol,Dept Med Oncol, Beijing, Peoples R China
[2] Peking Union Med Coll, Beijing, Peoples R China
[3] 3D Med Inc, Med Dept, Shanghai, Peoples R China
[4] Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e20514
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20514
引用
收藏
页数：1
相关论文
共 45 条
  • [41] Analytic validation and clinical feasibility of a next-generation sequencing assay to assess tumor mutational burden from blood (bTMB) as a biomarker for anti-PD-L1 response in NSCLC
    Lieber, Daniel S.
    White, Emily
    Silterra, Jacob
    Zhong, Shan
    Brennan, Tina
    Coyne, Michael
    Kennedy, Mark
    Gandara, David R.
    Kowanetz, Marcin
    Paul, Sarah M.
    Schleifman, Erica
    Li, Yan
    Rittmeyer, Achim
    Fehrenbacher, Louis
    Amler, Lukas
    Riehl, Todd
    Cummings, Craig
    Hegde, Priti S.
    Zou, Wei
    Sandler, Alan
    Ballinger, Marcus
    Mok, Tony
    Shames, David S.
    Lipson, Doron
    Malboeuf, Christine
    Fabrizio, David
    CANCER IMMUNOLOGY RESEARCH, 2018, 6 (09)
  • [42] Blood-based genomic profiling of cell-free DNA (cfDNA) to identify microsatellite instability (MSI-H), tumor mutational burden (TMB) and Wnt/B-Catenin pathway alterations in patients with gastrointestinal (GI) tract cancers.
    Isaacs, James
    Nixon, Andrew B.
    Bolch, Emily
    Quinn, Katie
    Banks, Kimberly
    Hanks, Brent Allen
    Strickler, John H.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [43] Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)
    Kim, E. S.
    Velcheti, V.
    Mekhail, T.
    Leal, T. A.
    Dowell, J. E.
    Tsai, M. L.
    Dakhil, C. S. R.
    Stella, P.
    Shen, V.
    Hu, S.
    Paul, S. M.
    Shames, D. S.
    Schleifman, E.
    Fabrizio, D. A.
    Yun, C.
    Phan, S.
    Socinski, M. A.
    ANNALS OF ONCOLOGY, 2018, 29 : 744 - 744
  • [44] Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)
    Socinski, M.
    Velcheti, V.
    Mekhail, T.
    Chae, Y. K.
    Leal, T. A.
    Dowell, J. E.
    Tsai, M. L.
    Dakhil, C. S.
    Stella, P.
    Shen, V.
    Hu, S.
    Paul, S. M.
    Shames, D. S.
    Schleifman, E.
    Fabrizio, D. A.
    Nowicki, M.
    Yun, C.
    Phan, S.
    Kim, E. S.
    ANNALS OF ONCOLOGY, 2019, 30 : 919 - +
  • [45] Circulating tumor DNA (ctDNA) positivity and its association with clinicopathological characteristics by novel blood-based test for colorectal cancer (CRC) screening from a multi-center large cohort: COSMOS-CRC-01.
    Murano, Tatsuro
    Ikematsu, Hiroaki
    Matsuhashi, Nobuhisa
    Shiozawa, Manabu
    Kato, Takeshi
    Oki, Eiji
    Goto, Masahiro
    Kagawa, Yoshinori
    Kanazawa, Akiyoshi
    Ohta, Takashi
    Ouchi, Akira
    Bando, Hideaki
    Uchigata, Hiroshi
    Notake, Chiemi
    Forouzmand, Elmira
    He, Yupeng
    Raymond, Victoria M.
    Duenwald, Sven
    Yoshino, Takayuki
    Nakamura, Yoshiaki
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 69 - 69
12345